SAN DIEGO, Dec. 9 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery, today announced the initiation of a dose-finding study designed to evaluate the safety and efficacy of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock. MP4OX is a novel oxygen therapeutic agent that is designed to provide rapid oxygen delivery to ischemic tissues.
The clinical trial will be a multi-center, randomized, double-blind, controlled study that will enroll up to 75 patients who have suffered hemorrhagic shock with lactic acidosis across approximately 12 trial sites in Europe and South Africa. The primary objective of the study is to measure reduction in lactate levels after infusion of MP4OX. Acute traumatic injury, including both blunt and penetrating trauma is often associated with severe bleeding which can lead to hemorrhagic shock. During shock, inadequate perfusion of critical organs can lead to insufficient oxygenation of tissues, which can be detected by an increase in lactate levels.
Physical trauma is a serious injury to the body. According to the Centers for Disease Control and Prevention (CDC), unintentional injury kills more people between the ages of one and 44 than any other disease or illness.
About Trauma
Traumatic injuries, including both penetrating trauma injuries such as bullet and knife wounds and blunt trauma from car accidents and falls, cause the death of over 5 million people each year world-wide. Trauma is the leading cause of death in people under the age of 44. Despite optimal care, many patients treated for traumatic injuries suffer organ dysfunction and failure. Elevated lactate levels (lactic acidosis), which indicate hypoperfusion and anaerobic metabolism (oxygen deprivation) in tissues and organs in the body, represent metabolic failure and also cardiovascular, renal and hepatic dysfunction. Prolonged lactic acidosis correlates with worse outcomes and higher mortality.
To learn more about Sangart, please visit the company’s website at www.sangart.com.
Sangart, Inc.
